Brief email update from Leo, nothing ground breaking, but as always good to see the excellent communication with shareholders.

I asked him as follows : Aside from PRs, are there any planned or any in the works plans to communicate trial data in ways besides issuing PRs?




The responses:
I will be communicating with shareholders quite regularly. Although there may not be an update every week, be advised that Kevetrin clinical studies are progressing, and Dr Reddys Labs are progressing in the manufacture of Prurisol. As soon as I receive relevant information, I will issue a press release. Besides regular press releases we anticipate presenting data at this coming 2013 ASCO meeting.

Happy Thanksgiving

Best wishes,

Leo Ehrlich


You really have to love the excellent communication with shareholders, it is very reassuring.